Company intelligence / Profile preview
Institute of Medicinal Molecular Design, Inc.
- Ownership
- Private
- Employees
- ~57
- Development stage
- Other
Overview
IMMD has developed a proprietary rational drug design platform that enables rapid identification and optimization of small molecule drug candidates using advanced virtual screening and docking methods. The company has completed a Phase I clinical trial for IMD‑0354 ointment for atopic dermatitis, confirming its safety profile. Other programs are in preclinical stages targeting thrombosis, atherosclerosis, Alzheimer's disease, and vascular dementia with novel mechanisms such as non‑ATP‑competitive inhibition for IKKβ inhibitors and plasminogen activator inhibitor‑1 inhibition.[7][5]
- Therapeutic areas
- NeurologyCardiovascularDermatology
- Modalities
- Small molecules[1][2][7]
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Institute of Medicinal Molecular Design, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Institute of Medicinal Molecular Design, Inc..